Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.36 |
| ▸ | EDNRB | P24530 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14746215 | 0.92 | MEN1 (0.40) | MEN1KMT2ALMNAKDM4ETSHR | |
| SCHEMBL14746077 | 0.86 | TSHR (0.37) | MEN1KMT2ATSHREGLN1EDNRB | |
| SCHEMBL14745862 | 0.83 | EGLN1 (0.40) | MEN1KMT2ATP53KDM4ETSHR | |
| SCHEMBL14746276 | 0.83 | EGLN1 (0.40) | MEN1KMT2AKDM4ETSHREGLN1 | |
| SCHEMBL17495073 | 0.80 | EGLN1 (0.38) | MEN1KMT2ALMNATP53KDM4E | |
| SCHEMBL14745969 | 0.79 | ALDH1A1 (0.39) | MEN1KMT2ALMNATP53TSHR | |
| SCHEMBL14741316 | 0.78 | EGLN1 (0.39) | MEN1KMT2ALMNATP53TSHR | |
| SCHEMBL14746011 | 0.76 | EGLN1 (0.42) | MEN1KMT2ATP53KDM4ETSHR | |
| SCHEMBL16568122 | 0.75 | MEN1 (0.41) | MEN1KMT2AKDM4EEGLN1EDNRB | |
| SCHEMBL17495015 | 0.75 | MAPT (0.38) | MEN1KMT2ATP53KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2750678-B1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. | 2015-02-05 | — | — | US | disclosed |
| EP-2750678-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033228-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | MEN1 4630/4885KMT2A 4450/4885LMNA 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.